Compare Ginkgo Bioworks Holdings Inc (DNA) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Gitlab Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M), while Gitlab Inc trades at $40.8 (market cap $7.11B). The key difference: Gitlab Inc is far larger — about 14.1× Ginkgo Bioworks Holdings Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | GTLB | |
|---|---|---|
Market Cap | $505.73M | $7.11B |
Sector | Health | Technology |
52-Week High | $16.14 | $51.04 |
52-Week Low | $5.48 | $19.42 |
Enterprise Value | $607.68M | $5.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.
DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.
GitLab (GTLB) trades at $40.93, up 0.49% today, with a bullish technical signal from moving averages but overbought RSI readings above 90. The company reported strong revenue growth, reaching $759 million in 2025, and has beaten EPS estimates for three consecutive quarters. Recent news highlights its leadership in DevSecOps and AI-driven platform enhancements, including the launch of GitLab 19.2 and a collaboration with Google Cloud.
Outlook remains mixed; analyst consensus is cautious with a $32.92 price target below the current price, citing high valuation multiples like a P/E of 521.22. Risks include persistent negative cash flow and profitability challenges, though growth in AI and enterprise adoption offers long-term potential. Investors should weigh high valuation against robust revenue expansion and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
